{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:13:34Z","timestamp":1764260014161,"version":"build-2065373602"},"reference-count":0,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[1993,11,1]],"date-time":"1993-11-01T00:00:00Z","timestamp":752112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The FASEB Journal"],"published-print":{"date-parts":[[1993,11]]},"abstract":"<jats:p>\n                    Cell\u2010mediated contraction of tissues containing fibrillar collagene can lead to organ compromise and loss of function. The same process that is biologically advantageous during the contraction phase of wound healing can be subverted in diseases such as hepatic cirrhosis, pulmonary fibrosis, and scleroderma, although the cellular and molecular mechanism of matrix tissue contraction is difficult to study in such chronic diseases. However, certain human eye diseases that result in tractional detachment of the retina and loss of vision are characterized by acute cell\u2010mediated contraction of collagenous tissue in the vitreous cavity. In this study, we demonstrate that human cells can contract vitreous, a complex biological gel containing type II collagen, in vitro. This cell\u2010mediated contraction can be blocked by antibodies and peptides that antagonize the function of\n                    <jats:italic>\u03b1<\/jats:italic>\n                    <jats:sub>2<\/jats:sub>\n                    <jats:italic>\u03b2<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    integrin, and the potential for contraction can be conferred upon noncontracting cells by stable transfection of cells with\n                    <jats:italic>\u03b1<\/jats:italic>\n                    <jats:sub>2<\/jats:sub>\n                    cDNA. We also show that this contractile process, if focally resisted, can result in remodeling vitreous from a gel to a structure that resembles a planar membrane, and that substantial isometric forces can be measured across this tissue. We propose that in diseases such as proliferative diabetic retinopathy and proliferative vitreoretinopathy,\n                    <jats:italic>\u03b1<\/jats:italic>\n                    <jats:sub>2<\/jats:sub>\n                    <jats:italic>\u03b2<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    integrin\u2010mediated contraction of the vitreous and tension at the site of vitreoretinal attachments contribute to the terminal event of tractional retinal detachment. By extension, we propose that\n                    <jats:italic>\u03b1<\/jats:italic>\n                    <jats:sub>2<\/jats:sub>\n                    <jats:italic>\u03b2<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    integrin is a centrally important molecule in human diseases characterized by remodeling and contraction of collagenous tissue (i.e., fibrocontractive diseases).\u2014Kupper, T. S., Ferguson, T. A. A potential pathophysiologic role for\n                    <jats:italic>\u03b1<\/jats:italic>\n                    <jats:sub>2<\/jats:sub>\n                    <jats:italic>\u03b2<\/jats:italic>\n                    <jats:sub>1<\/jats:sub>\n                    integrin in human eye diseases involving vitreoretinal traction.\n                    <jats:italic>FASEB J.<\/jats:italic>\n                    7: 1401\u20101406; 1993.\n                  <\/jats:p>","DOI":"10.1096\/fasebj.7.14.8224612","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T06:27:06Z","timestamp":1516861626000},"page":"1401-1406","source":"Crossref","is-referenced-by-count":17,"title":["A potential pathophysiologic role for\n                    <i>\u03b1<\/i>\n                    <sub>2<\/sub>\n                    <i>\u03b2<\/i>\n                    <sub>1<\/sub>\n                    integrin in human eye diseases involving vitreoretinal traction"],"prefix":"10.1096","volume":"7","author":[{"given":"Thomas S.","family":"Kupper","sequence":"first","affiliation":[{"name":"Division of Dermatology Harvard Medical School at Brigham and Women's Hospital Boston Massachusetts 02115 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Washington University St. Louis Missouri 63110 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1993,11]]},"container-title":["The FASEB Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fasebj.7.14.8224612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fasebj.7.14.8224612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:20:57Z","timestamp":1761693657000},"score":1,"resource":{"primary":{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/10.1096\/fasebj.7.14.8224612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,11]]},"references-count":0,"journal-issue":{"issue":"14","published-print":{"date-parts":[[1993,11]]}},"alternative-id":["10.1096\/fasebj.7.14.8224612"],"URL":"https:\/\/doi.org\/10.1096\/fasebj.7.14.8224612","archive":["Portico"],"relation":{},"ISSN":["0892-6638","1530-6860"],"issn-type":[{"type":"print","value":"0892-6638"},{"type":"electronic","value":"1530-6860"}],"subject":[],"published":{"date-parts":[[1993,11]]}}}